Physician profile
Mohammad A Arain
NPI 1639167158
$2,234.44
in general payments reported to CMS, 2019-2025
21 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $340 · 2021: $501 · 2022: $349 · 2023: $380 · 2024: $201 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $707.73 | 2019-2025 | |
| Amgen INC. | $444.66 | 2019-2024 | Repatha |
| Glaxosmithkline, LLC. | $202.84 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $127.06 | 2023 | Camzyos |
| Exact Sciences Corporation | $111.48 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $98.65 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $83.59 | 2020-2025 | Breztri |
| Lilly USA, LLC | $80.06 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $66.32 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $60.21 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.68 | 2020-2021 | |
| Esperion Therapeutics, INC. | $28.87 | 2020 | |
| Sanofi Pasteur INC. | $24.99 | 2022 | |
| Biosense Webster, INC. | $23.30 | 2021 | |
| Merck Sharp & Dohme LLC | $22.67 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $22.45 | 2019-2021 | |
| Abiomed | $21.67 | 2024 | Impella |
| Abbott Laboratories | $19.33 | 2021 | |
| Allergan, INC. | $16.83 | 2020 | |
| Abbvie INC. | $14.09 | 2021 | |
| Mannkind Corporation | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Arain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.